


Chemical Science

Volume 14
Number 24
28 June 2023
Pages 6479–6808

rsc.li/chemical-science



ISSN 2041-6539

EDGE ARTICLE

Raúl García-Rodríguez *et al.*
Structural and dimensional control of porphyrin capsules
using Group 15 tris(3-pyridyl) linkers

Cite this: *Chem. Sci.*, 2023, 14, 6522

All publication charges for this article have been paid for by the Royal Society of Chemistry

Structural and dimensional control of porphyrin capsules using Group 15 tris(3-pyridyl) linkers†

Álvaro García-Romero,^a Daniel Miguel,^a Dominic S. Wright,^b Celedonio M. Álvarez^a and Raúl García-Rodríguez^{a*}

While supramolecular chemistry involving organic and metallo-organic host assemblies is a well-established and important field with applications in gas-storage, drug-delivery and the regio- and stereo-control of organic reactions, the use of main group elements in this setting (beyond the second row of the p-block) has been little explored. In this paper we show how periodic trends in the p-block can provide the means for systematic size and structural control in an important class of supramolecular porphyrin-based capsules. The formation of molecular and extended 2D capsule arrangements between the heavier Group 15 tris(3-pyridyl) linkers Sb(3-py)₃ and Bi(3-py)₃ and the metallo-porphyrins MTPP (M = Zn, Mg; TPP = tetraphenylporphyrin, 3-py = 3-pyridyl) is the first study involving heavier Group 15 pyridyl linkers. The increase in C–E bond length in the E(3-py)₃ linkers moving down Group 15 (from E = P, to Sb, to Bi) can be used to alter the dimensions and structural preference of the capsules, as can oxidation of the Group 15 bridgehead atoms themselves. The subtle changes in the dimensions and Lewis acidity of the encapsulates have a dramatic effect on the rate and selectivity of the catalytic oxidative cleavage of organic diols and catalytic oxidation of α-hydroxyketones. By providing simple tools for modulating the chemical and steric properties of the capsules this work should have direct applications for the tuning of the activity and specificity of a range of catalytic systems based on main-group-based capsules of this type.

Received 27th April 2023
Accepted 16th May 2023

DOI: 10.1039/d3sc02151c

rsc.li/chemical-science

Introduction

Nature represents a perennial source of inspiration for researchers for the design and function of molecules. Enzymes exhibit exquisite selectivity in substrate binding and reactivity through the shape and electronic complementarity of the binding pocket around the active site. To mimic the chemical control and abilities of enzymes, researchers have designed various capsule-like structures with well-defined cavities reminiscent of the enzymatic active site.^{1–3} These systems offer the possibility to achieve specific encapsulation, binding, or controlled passage of guest molecules.⁴ As a result, they have attracted strong research interest across multiple research areas, with applications in drug delivery,^{5,6} sensing and imaging,^{7,8} gas storage,^{9–12} molecular separation,^{13,14} and catalysis.^{15–18} Confinement within the cavity can lead to

enhanced reactivity of the guest or unique reaction selectivity, or conversely, the stabilization of a reactive guest molecule.^{19–21} In particular, since the 1990s, there has been increasing interest in the study of the application of molecular capsules as nano-reactors for a number of chemical reactions.^{17,20,22–27} The microenvironment within the capsules (*i.e.*, the shape, size, and chemical properties of the cavity) is key, and thus, full realization of these applications requires very fine structural control over the capsule architecture to tailor the cavity for specific host-guest interactions. Despite the vast number of capsules that have been described over the years and the efforts towards the design and control of these attractive systems,^{28–32} the use of relatively heavy p-block elements as a means to achieve fine structural control is surprisingly very limited.

In this context, capsules based on tris(3-pyridyl)phosphine have emerged as a novel way to obtain encapsulated transition metal catalysts.^{25–27} The first capsule-forming example {[P(3-py)₃]₃·(ZnTPP)₃} (3-py = 3-pyridyl, TPP = tetraphenylporphyrin) was described in 2001,³³ and the single-crystal X-ray structure was reported in 2013 by Reek and co-workers (Fig. 1).³⁴ These capsules are of interest not only for the aesthetic aspects of their supramolecular arrangements, but also for their confinement of single-site Pd- and Rh-based catalysts, which results in rate acceleration and the unprecedented selective hydroformylation of terminal and internal

^aGIR MIOMeT-IU Química-Química Inorgánica Facultad de Ciencias, Universidad de Valladolid, Campus Miguel Delibes, 47011 Valladolid, Spain. E-mail: raul.garcia.rodriguez@uva.es

^bChemistry Department, Cambridge University, Lensfield Road, Cambridge CB2 1EW, UK

† Electronic supplementary information (ESI) available: Experimental details, NMR and mass-spectrometry data, DFT calculations and X-ray single-crystal structure details. CCDC 2195694–2195704. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d3sc02151c>




Fig. 1 First example of a $\{[P(3\text{-py})_3] \cdot (ZnTPP)_3\}$ assembly.

alkenes.^{33,35–40} The binding of substrates to the constrained metal centres in these capsules restricts their possible reaction pathways, leading to greater regioselectivity than that of the unencapsulated catalysts. Studies of capsules based on $P(3\text{-py})_3$ with various substituted porphyrins have demonstrated that small distortions in the capsule shape have a critical impact on selectivity.^{34,36,37,41}

In addition to varying the nature of and substituents present on the porphyrins, another potential way of modifying the dimensions and coordination characteristics of the capsules is changing the bridgehead atom present in the tris(3-pyridyl) linker unit. We have very recently developed synthetic approaches to metallic or semi-metallic tris-pyridyl ligands,^{42–47} including the heavier Group 15 ligands $E(3\text{-py})_3$ [$E = \text{Sb}$ (1), Bi (2)] (Fig. 2a),⁴⁸ and shown that the latter can be employed in the construction of a series of hybrid MOF arrangements with Cu^+ and Ag^+ ($=M^+$) salts, in which the ligands adopt a tetradentate N_3N,E -bonding mode.⁴⁸ As shown in Fig. 2b, these MOFs consist of E_4M_4 cubane units in which the anions are encapsulated.

Having illustrated that the new heavy Group 15 ligands can be employed as linkers in supramolecular assemblies, we turn

our attention here to their use in capsule formation with metalloporphyrins. The periodic effects of changing the bridgehead atom on the E–C bond length and C–E–C bond angle,⁴⁹ we reasoned, should have a direct impact on the microenvironment of capsules of this type and provide a valuable toolkit for tailoring their cavities for specific host–guest and catalysis chemistry. In the current study, we show how the bridgehead atom can be used to modulate the properties of these capsules and control their size and shape.

Results and discussion

Effect of the bridgehead atom

To evaluate whether capsule formation was possible using 1 and 2, we first explored their coordination with zinc tetraphenylporphyrin (ZnTPP). The addition of ZnTPP to a solution of ligands 1 or 2 in CDCl_3 (3 : 1) resulted in a large upfield shift of the ^1H NMR signals of the pyridyl ring due to the porphyrin ring-current effect, which was indicative of axial binding of the pyridine nitrogen to the Zn(II) metalloporphyrin. Slow diffusion of *n*-hexane into a CHCl_3 solution of ligands 1 or 2 (1 equiv.) and ZnTPP (3 equiv.) over a week gave dark purple hexagonal crystals of $\{[E(3\text{-py})_3] \cdot (ZnTPP)_3\}$ ($E = \text{Sb}$ (1·Zn), Bi (2·Zn)) in 62 and 58% yields, respectively (Scheme 1). The room-temperature ^1H NMR spectra of 1·Zn and 2·Zn in CDCl_3 indicated a 1 : 3 ratio of 1 or 2 to ZnTPP. Further confirmation of the formation of 1 : 3 complexes was provided by ESI-TOF high-resolution mass spectrometry, which showed the expected $[M + H]^+$ peak at m/z 2390.4940 (calcd 2390.4957) for 1·Zn and 2478.5664 (calcd 2478.5719) for 2·Zn (see ESI†).

Crystallographic analysis of 1·Zn and 2·Zn confirms the formation of capsules for both, but reveals that bulk samples contain mixtures of crystals in which two different conformations of the capsules are present. In crystals of the ‘closed’ (or ‘in’) conformation the porphyrin rings are approximately perpendicular to each other, forming a roughly cylindrical arrangement, while in the ‘open’ conformation one of the porphyrin units is displaced downwards with respect to the other two (see Fig. 3 and 6 and later discussion). These two conformations therefore allow different accessibility to the





Fig. 2 (a) Antimony- and bismuth-based tris(3-pyridyl) ligands. (b) The E_4M_4 unit in the MOFs formed by coordination of 1 and 2 with Cu^+ and Ag^+ salts.



Scheme 1 Synthesis of the capsules $\{[Sb(3\text{-py})_3] \cdot (ZnTPP)_3\}$ (1·Zn) and $\{[Bi(3\text{-py})_3] \cdot (ZnTPP)_3\}$ (2·Zn).






Fig. 3 Possible conformations of capsules of the type $[(E(3\text{-py})_3) \cdot (\text{ZnTPP})_3]$.

cavities. In previous structural studies of $\{[\text{P}(3\text{-py})_3] \cdot (\text{Zn-porphyrin})_3\}$ systems, only the closed conformation has been identified.^{34,40} In theory the rotation of all three pyridyl rings




Fig. 4 X-ray structures of the complexes **1**·Zn-closed (a) and **2**·Zn-closed (b). In both structures, the ligand coordinates three porphyrins through N–Zn interactions, leading to the formation of capsule-type structures. Solvent molecules and H-atoms are omitted for clarity. Selected bond lengths (Å) and angles (°): **1**·Zn, Sb–C_{py} range 2.146(5)–2.158(5); N_{py}–Zn range 2.149(4)–2.194(4); C_{py}–Sb–C_{py} range 95.4(2)–96.0(2). **2**·Zn, Bi–C_{py} range 2.235(6)–2.261(5); N_{py}–Zn range 2.149(5)–2.184(5); C_{py}–Bi–C_{py} range 93.0(2)–94.2(2). Colour key: C (grey), Zn (dark grey), N (blue), P (orange), Sb (light purple), Bi (purple). X-ray structures of $[\text{P}(3\text{-py})_3] \cdot (\text{ZnTPP})_3$ (c), **1**·Zn (d) and **2**·Zn (e) showing the capsules with close intramolecular CH– π interactions between ZnTPP building blocks highlighted in red and interactions between C–H pyridyl and ZnTPP highlighted in green. CH– π interaction lengths (Å): $[\text{P}(3\text{-py})_3] \cdot (\text{ZnTPP})_3$ 2.725, 2.893 and 2.960;³⁴ **1**·Zn 2.971, 3.051 and 2.978 (CH_{py}– π); **2**·Zn 2.991, 3.025 and 2.978 (CH_{py}– π).




Fig. 5 (a) Trends in the average C–E–C angles (green) and E–C distances (red) in the X-ray structures of the capsules (E = P, Sb and Bi). Colour key: C (grey), N (blue), P (orange), Sb (light purple), Bi (purple). (b) Linear correlation between the covalent radii of the bridgehead atom and the effective size of the capsule ($D_{\text{Zn–Zn}}$) in the X-ray structures of $[\text{P}(3\text{-py})_3] \cdot (\text{ZnTPP})_3$, **1**·Zn-closed and **2**·Zn-closed.

about the E–C_{py} bonds could lead to a conformation in which the three porphyrins are pointed down, in which E is de-encapsulated (the “out” conformer, Fig. 3). However, this possibility can be discarded in the case of ZnTPP units due to the steric hindrance between the three porphyrin rings, although it is possible for smaller building blocks such as Zn(II) salphens.³⁸ The open conformer that we have characterised here is the first reported observation of this form.

1·Zn-closed and **2**·Zn-closed are isostructural in the solid state. The ligands **1** and **2** link the porphyrin-bound Zn²⁺ centres *via* their three 3-Py N-donor atoms, leading to bimetallic capsule arrangements (Fig. 4a and b). These arrangements are very similar to that found for $[\text{P}(3\text{-py})_3] \cdot (\text{ZnTPP})_3$ by Reek, in which the ligand is laterally flanked by the three porphyrins.³⁴ There are only minor geometric differences in the conformation of the porphyrin units due to the different geometric profiles of the heavier Group 15 ligands; one of the porphyrin arms is slightly tilted in **1**·Zn-closed and **2**·Zn-closed compared to $[\text{P}(3\text{-py})_3] \cdot (\text{ZnTPP})_3$. Despite their overall similarity, changing the bridging ligand has a direct impact on the size of the capsules. The reduction in the average C–E–C angle upon descending Group 15 (100.7, 95.8 and 93.8° for P, Sb and Bi, respectively) is offset by the increase in average E–C bond length (1.835, 2.152 and 2.249 Å for P, Sb and Bi, respectively) (Fig. 5a), but results overall in an increase in the size of the capsules from P to Sb to Bi. The average Zn···Zn distances in $[\text{P}(3\text{-py})_3] \cdot (\text{ZnTPP})_3$, **1**·Zn and **2**·Zn (9.905, 10.249 and 10.315 Å, respectively) correlate directly with the covalent radii of the Group 15 elements⁵⁰ of the bridgehead atom in the E(3-py)₃ ligands, which illustrates the capability of ligands **1** and **2** to modulate the cavity size (Fig. 5b – see also the discussion in the ESI†) of the “effective size” of the ligands within the capsules and the calculated volumes of the capsules.




Fig. 6 Solid-state structures of the closed-capsule conformer (a) and open-capsule conformer (b) of $1 \cdot \text{Zn}$. In the space-filling views of the X-ray structures (a and b, right), ligand **1** is indicated in red, and the three ZnTPP moieties in blue. Displacement ellipsoids at 50% probability. H-atoms are omitted for clarity. Colour key: C (grey), Zn (dark grey), N (blue), Sb (light purple). (c) Left: space-filling top view of the $1 \cdot \text{Zn}$ -closed conformer, showing one molecule of CHCl_3 present in the cavity; right: the same view with the molecule of CHCl_3 omitted, illustrating the accessibility of the antimony lone pair. (d) $1 \cdot \text{Zn}$ -open with the bridgehead Sb atom highlighted in red. Colour key: H (white), C (grey), N (blue), Sb (red), Cl (green).

The importance of attractive $\text{CH} \cdots \pi$ interactions between adjacent ZnTPP building blocks in $\{[\text{P}(3\text{-py})_3] \cdot (\text{ZnTPP})_3\}$ (Fig. 4c, red) has been noted previously.^{26,34} These interactions help to preserve the integrity and rigidity of the capsule, which are critical to their catalytic selectivity and activity since these will favour or disfavour alternative transition states.³⁴ Fig. 4d and e

show the three shortest $\text{CH} \cdots \pi$ distances found in $1 \cdot \text{Zn}$ -closed (range 2.971–3.051 Å) and $2 \cdot \text{Zn}$ -closed (2.978–3.025 Å). Unlike in $\{[\text{P}(3\text{-py})_3] \cdot (\text{ZnTPP})_3\}$, only two of these involve adjacent ZnTPP fragments (Fig. 4d and e, red), while the third $\text{CH} \cdots \pi$ interaction involves a CH group of the pyridyl ring and a ZnTPP unit (Fig. 4d and e, green). It is clear that due to the larger size of the capsules for $1 \cdot \text{Zn}$ and $2 \cdot \text{Zn}$, these $\text{CH} \cdots \pi$ interactions are lost or become weaker as compared with $\{[\text{P}(3\text{-py})_3] \cdot (\text{ZnTPP})_3\}$ (range 2.725–2.960 Å), which could lead to more flexible capsules.

Fig. 6 compares the structures of the open and closed conformers of $1 \cdot \text{Zn}$. A similar open conformer was also found for the bismuth capsule $2 \cdot \text{Zn}$ (see ESI Fig. S58†). As a result of the different arrangement of the ZnTPP units in the closed conformers, the lone pair of the bridgehead E atom is accessible for coordination (despite its poor donor properties, particularly for Sb) while in the open conformation, the orientation of two of the ZnTPP units blocks the lone pairs on the Sb and Bi centre (Fig. 6c right and Fig. 6d). The importance of the supramolecular conformation in this system is illustrated by the top-view of the space-filling representation of the structure of $1 \cdot \text{Zn}$ -closed, in which a CHCl_3 molecule (from crystallization) is located in the cavity of the capsule (Fig. 6c, left). The long $\text{Sb} \cdots \text{Cl}$ contact to the CHCl_3 molecule [3.752(2) cf. $\Sigma_{\text{VDW}}(\text{Sb}-\text{Cl}) = 3.81$]⁵¹ reflects the Lewis acidity of the Sb(III) and contributes to the stabilization of the CHCl_3 within the cavity, illustrating the effects of the heavy pnictogen atom in host–guest interactions. In contrast, in the top view of a molecule of $1 \cdot \text{Zn}$ -open, the lone pair of the antimony atom is completely blocked by the phenyl groups of the two upward-pointing porphyrins, preventing the possibility of solvent encapsulation (Fig. 6d). Additionally, variable-temperature NMR experiments in CDCl_3 showed that the building blocks of the capsules $1 \cdot \text{Zn}$ and $2 \cdot \text{Zn}$ are in fast exchange on the NMR timescale even at -60°C (similar to previous observations for the $\{[\text{P}(3\text{-py})_3] \cdot (\text{ZnTPP})_3\}$ capsule).³⁶ Therefore, no specific conclusions regarding the conformational preferences of the capsules in solution could be made (see ESI†).

DFT computational analysis in which free relaxation of the structure in gas phase was allowed using the APFD functional indicated that the open conformation is always the most stable for these capsules. However, its stability with respect to the closed conformer depends on the nature of E, and increases in the order $\text{Bi} \approx \text{Sb} > \text{P}$, with the Bi- and Sb-based capsules favouring the open conformer by 50.46 and 50.42 kJ mol^{-1} , respectively, compared to 45.35 kJ mol^{-1} for P. The greater preference for the open conformers of the Sb- and Bi-based capsules is probably steric in origin, reflecting the larger distance between the porphyrin units at their peripheries.

To obtain further insights into the thermodynamics of the formation of the supramolecular capsules $1 \cdot \text{Zn}$ and $2 \cdot \text{Zn}$ in solution, NMR titration experiments of the ligands $\text{E}(3\text{-py})_3$ [$\text{E} = \text{Sb}(1)$, $\text{Bi}(2)$] and ZnTPP in CDCl_3 were carried out. The titration curves could be fitted to a 1 : 3 model to give the association constants K_1 [$(9.2 \pm 1.9) \times 10^3 \text{ M}^{-1}$], K_2 [$(1.6 \pm 0.3) \times 10^3 \text{ M}^{-1}$] and K_3 [$(2.5 \pm 0.6) \times 10^2 \text{ M}^{-1}$] for $\text{Sb}(3\text{-py})_3$ to ZnTPP. Very similar results were obtained for $\text{Bi}(3\text{-py})_3$: K_1 [$(6.4 \pm 1.5) \times 10^3$

M^{-1}], $K_2 [(1.6 \pm 0.3) \times 10^3 \text{ M}^{-1}]$ and $K_3 [(3.8 \pm 0.9) \times 10^2 \text{ M}^{-1}]$ (see ESI† for further information). The titration studies show the expected decrease in binding affinities for systems lacking positive cooperativity. This is in contrast to the tendency of $\text{P}(3\text{-py})_3$ in the assembly $\{[\text{P}(3\text{-py})_3] \cdot (\text{ZnTPP})_3\}$, for which a positive cooperative effect was observed and was suggested to be the result of $\text{CH}-\pi$ interactions.^{34,36} The lack of cooperativity in our larger Sb and Bi capsules could be the result of the fewer and weaker $\text{CH}-\pi$ interactions between the porphyrin moieties observed in the solid-state structures of the closed conformers. This may also be affected by the greater preference for the open conformation of the Sb and Bi-based capsules. Additionally, the size of the capsules $1 \cdot \text{Zn}$ and $2 \cdot \text{Zn}$ in solution was studied through ^1H DOSY experiments in CDCl_3 . These studies yielded hydrodynamic radii of 7.49 and 7.50 Å for $1 \cdot \text{Zn}$ and $2 \cdot \text{Zn}$, respectively, which are about 80% of the crystallographic ones, in line with reports in the literature (see ESI†).^{52,53}

Effect of changing the metalloporphyrin unit

Inspired by these previous studies, we next investigated the effect of changing the metalloporphyrin unit on the supramolecular assemblies. No example of a capsule of this type containing a linker other than $\text{P}(3\text{-Py})_3$ has been structurally characterized previously, and all previous examples have employed Zn-containing metalloporphyrins. We reasoned that magnesium tetraphenylporphyrin (MgTPP) might be an ideal building block to obtain expanded supramolecular arrangements, since both axial positions at the Mg^{2+} centre are potentially available for coordination.^{54–57}

Slow diffusion of *n*-hexane into a CHCl_3 solution of the ligands $\text{P}(3\text{-py})_3$, **1** or **2** (2 equiv.) and (MgTPP) (3 equiv.) over a week gave dark-purple hexagonal crystals of $\{[\text{E}(3\text{-py})_3]_2 \cdot (\text{MgTPP})_3\}_n$ ($\text{E} = \text{P}$, Sb ($1 \cdot \text{Mg}$), Bi ($2 \cdot \text{Mg}$)) in 58%, 56% and 72% yield, respectively (Scheme 2).

Complexes $\text{P} \cdot \text{Mg}$, $1 \cdot \text{Mg}$ and $2 \cdot \text{Mg}$ have analogous structures in the solid-state in which the ligand molecules link three Mg^{2+} centres using the three 3-Py N-donor atoms and each Mg^{2+} centre is coordinated by two N-donor atoms of different ligand molecules, leading to a 2D polymeric arrangement formed by a sheet network consisting of E_6Mg_6 ($\text{E} = \text{P}$, Sb, Bi) ring units. Fig. 7a and b shows the structure of $1 \cdot \text{Mg}$ (see ESI† for the solid-





Fig. 7 (a) X-ray structure showing the 2D polymeric arrangement of $1 \cdot \text{Mg}$. Pyridyl coordination at both axial positions of MgTPP results in an extended structure. The inset shows the capsule that results from the coordination of **1** to three MgTPP units. H atoms and CHCl_3 solvent molecules are omitted for clarity. Selected bond lengths (Å) and angles ($^\circ$): $1 \cdot \text{Mg}$, Sb–C_{py} 2.155(4); N_{py}–Zn 2.330(2); C_{py}–Sb–C_{py} 94.6(2). Colour key: C (grey), N (blue), Sb (light purple), Mg (red). (b) X-ray structure of the 2D polymeric structure of $1 \cdot \text{Mg}$ showing the 2-D network structure consisting of Sb_6Mg_6 ring units, which leads to the formation of hexagonal voids in the structure (inset). (c) Linear correlation between the covalent radii of the bridgehead atom and the effective size of the hexagonal voids ($D_{\text{H-H}}$) in the X-ray structures of $\text{P} \cdot \text{Mg}$, $1 \cdot \text{Mg}$ and $2 \cdot \text{Mg}$. Colour key: C (grey), N (blue), Sb (light purple), Mg (red).



Scheme 2 Synthesis of the complexes $\{[\text{P}(3\text{-py})_3]_2 \cdot (\text{MgTPP})_3\}_n$ ($\text{P} \cdot \text{Mg}$), $\{[\text{Sb}(3\text{-py})_3]_2 \cdot (\text{MgTPP})_3\}_n$ ($1 \cdot \text{Mg}$) and $\{[\text{Bi}(3\text{-py})_3]_2 \cdot (\text{MgTPP})_3\}_n$ ($2 \cdot \text{Mg}$).

state structures of $\text{P} \cdot \text{Mg}$ and $2 \cdot \text{Mg}$). Surprisingly, the integrity of the monomeric capsule structure is still preserved in the polymeric arrangement (Fig. 7a, inset), forming a hybrid structure in which the capsules are assembled into an expanded 2D network using both axial positions of the magnesium metalloporphyrin (Fig. 7a). The presence of six-coordinate Mg^{2+} instead of five-coordinate Zn^{2+} in the porphyrin core also leads to greater M–N bond lengths of the $\text{E}(3\text{-py})_3$ N-atoms (range 2.149(4)–2.194(4) Å for Zn derivatives vs. range 2.324(3)–2.374(2) Å for Mg derivatives). Consequently, there is an increase in the capsule

Complex $3 \cdot \text{Zn}$ has a similar structure to $1 \cdot \text{Zn}$ and $2 \cdot \text{Zn}$ in the solid state, in which the ligand molecules link Zn^{2+} centres using the three 3-Py donor-N atoms, leading to the formation of a capsule arrangement (Fig. 8b). The change in the geometry at the Sb centre results in an increase in the C–Sb–C angles (range $115.6(2)$ – $128.3(2)^\circ$ vs. range $95.4(2)$ – $96.0(2)^\circ$ for $3 \cdot \text{Zn}$ and $1 \cdot \text{Zn}$ -closed, respectively). This leads to a change in not only the

¹H NMR studies of **P**·Mg, **1**·Mg and **2**·Mg in CDCl₃ show large characteristic upfield shifts in the proton signals of the pyridyl ring in the E(3-py)₃ (E = P, Sb, Bi) ligand, which are indicative of the coordination of the pyridine nitrogen to the Mg(II)-TPP metalloporphyrin. The aggregation state of the Mg(II) complexes in solution was studied *via* ¹H DOSY experiments, which indicated the collapse of the polymeric structures observed in the solid state for all three compounds, and suggested the presence of small aggregates in solution (see ESI† for details). However, the formation of discrete capsules was observed by mass spectrometry (ESI-TOF, see ESI†).

Ligands $\text{Cl}_2\text{Sb}^{\text{V}}(\text{3-py})_3$ (**3**) and $\text{Cl}_2\text{Bi}^{\text{V}}(\text{3-py})_3$ (**4**) were easily obtained by the oxidation of **1** and **2**, respectively, with 1 equiv. of SO_2Cl_2 in DCM. This enables the change from a pyramidal coordination node in the E(m) ligands **1** and **2** to a trigonal planar coordination node in the E(v) ligands **3** and **4**, providing a way to modulate the coordination mode of the antimony and bismuth ligands. Compounds **3** and **4** were characterized using




Fig. 8 (a) Synthesis of **3**·Zn. (b) X-ray structure of the complex **3**·Zn. The ligand coordinates three porphyrins through N–Zn interactions. As a result of the coordination, the ligand is fenced by the three porphyrins, leading to the formation of a capsule-type structure. The three CHCl₃ molecules located in the unit cell are omitted for clarity. (c) Space-filling view of the compound **3**·Zn, in which two CHCl₃ molecules are accommodated in the capsule cavity. Displacement ellipsoids at 50% probability. H atoms are omitted for clarity. Selected bond lengths (Å) and angles (°): **3**·Zn, Sb–C_{py} range 2.109(4)–2.119(4); N_{py}–Zn range 2.178(4)–2.228(4); Sb–Cl 2.423(1) and 2.460(1); C_{py}–Sb–C_{py} range 115.6(2)–128.3(2). Colour key: C (grey), Zn (dark grey), N (blue), Sb (light purple), Cl (green).




Fig. 9 (a) Synthesis of $3 \cdot \text{Mg}$. (b) X-ray structure of the 1D polymeric structure of $3 \cdot \text{Mg}$ through $\text{N} \cdots \text{Mg}$ interactions. Displacement ellipsoids at 50% probability. H atoms are omitted for clarity. Selected bond lengths (Å) and angles ($^\circ$): $3 \cdot \text{Mg}$, $\text{Sb}-\text{C}_{\text{py}}$ range 2.102(3)–2.123(3); $\text{N}_{\text{py}}-\text{Zn}$ 2.380(2) and 2.385(2); $\text{Sb}-\text{Cl}$ 2.4348(9) and 2.4426(9); $\text{C}_{\text{py}}-\text{Sb}-\text{C}_{\text{py}}$ range 119.4(1)–120.6(1). Colour key: C (grey), Cl (green), N (blue), Sb (light purple) and Mg (red).

shape but also the size of the capsule (average $D_{\text{Zn} \cdots \text{Zn}}$ 10.462 vs. 10.249 Å for $3 \cdot \text{Zn}$ and $1 \cdot \text{Zn}$ -closed, respectively). The increased size of the capsule arrangement is illustrated by the presence of two CHCl_3 molecules inside the cavity instead of the one observed in the CHCl_3 solvate of $1 \cdot \text{Zn}$ (cf. Fig. 6c and 8c).

In contrast to the $\text{Sb}(\text{III})$ ligand **1**, the reaction of ligand **3** and magnesium tetraphenylporphyrin (MgTPP) did not form a 3D capsule arrangement, instead giving the 1D coordination polymer $[\{\text{Cl}_2\text{Sb}^{\text{V}}(3\text{-py})_3\}(\text{MgTPP})]_n$ ($3 \cdot \text{Mg}$). Although its formation was observed regardless of the stoichiometry used (3 : MgTPP ratios of 1 : 2 or 1 : 3), better yields (34%) were obtained using the required 1 : 1 stoichiometry (see ESI†). Fig. 9 shows the 1D polymeric structure of $3 \cdot \text{Mg}$ in the solid state. The $\text{Sb}(\text{V})$ ligands **3** link the Mg^{2+} centres in a polymeric arrangement using two 3-Py N donor atoms (the third remains uncoordinated) (Fig. 9b). The change in geometry of the linker from pyramidal in $\text{Sb}(\text{III})$ **1** to trigonal planar in $\text{Sb}(\text{V})$ **3** precludes the formation of the hybrid 2D capsule arrangement observed for $1 \cdot \text{Mg}$, resulting in the formation of the 1D zig-zag structure of $3 \cdot \text{Mg}$.

Preliminary catalytic studies

In recent years, there has been dramatic progress in organo-pnictogen catalysis and in particular growing interest in catalytic redox reactions.^{49,59} To the best of our knowledge the catalytic redox behaviour of organo-bismuth and -antimony compounds has not been explored in a confined environment. We decided to study the effect of the encapsulation of the bismuth center in the catalytic oxidative cleavage of 1,2-diols, which constitutes one of the first bismuth redox catalytic systems developed.

Barton and, more recently, Cornella, reported the bismuth redox catalytic behavior of several bismuthines, showing that catalytic amounts of the bismuth(III)-containing species are able

Table 1 Oxidative cleavage of 1,2-diols in the presence of **2** or $2 \cdot \text{Zn}$ ^a

Entry	Bi catalyst	Yield (%)		
		R = Me	R = Ph	
1	2	65	—	
2	$2 \cdot \text{Zn}$	16	—	
3	2	—	31	
4	$2 \cdot \text{Zn}$	—	38	
Competitive ^b				
5	2	76	20	
6	$2 \cdot \text{Zn}$	18	63	

^a Oxidative cleavage of 1,2-diols in the presence of **2** or $2 \cdot \text{Zn}$. Reaction conditions: 1,2-diol (0.14 mmol), NBS (0.14 mmol), K_2CO_3 (1.4 mmol), 1.5 ml of CD_3CN at 25 $^\circ\text{C}$. ^b Reaction conditions: 1,1,2,2-tetramethyl-1,2-ethanediol (0.07 mmol), 1,1,2,2-tetraphenyl-1,2-ethanediol (0.07 mmol), NBS (0.14 mmol), K_2CO_3 (1.4 mmol), 1.5 ml of CD_3CN at 25 $^\circ\text{C}$. Yields were determined by ^1H NMR after 90 min.

to catalyze the oxidative cleavage of 1,2-diol in the presence of *N*-bromo-succinimide (NBS) as a stoichiometric oxidant.^{60–62} With this in mind, we evaluated the catalytic behavior of our tris(3-pyridyl)bismuthine (**2**) in the oxidative cleavage of two well-studied substrates, pinacol ($\text{Me}_2\text{C}(\text{OH})\text{C}(\text{OH})\text{Me}_2$) and benzopinacol ($\text{Ph}_2\text{C}(\text{OH})\text{C}(\text{OH})\text{Ph}_2$), using the reaction conditions established by Barton.⁶¹ When the reaction of pinacol was carried out in the absence of BiPy_3 (**2**) (either with or without ZnTPP metalloporphyrin), formation of Me_2CO was not observed, proving the necessity of bismuth as a catalyst, as previously reported^{60–62} (see ESI†). In contrast, the presence of 1 mol% of the ligand **2** produces the cleavage of pinacol, yielding acetone (Table 1, entry 1). Under the same conditions, $\text{Ph}_2\text{C}(\text{OH})\text{C}(\text{OH})\text{Ph}_2$ also gave the corresponding oxidative cleavage product benzophenone (entry 3), albeit at a slower rate, which parallels early observations by Barton. Having demonstrated catalysis in the presence of **2**, we next explored the effect of its encapsulation. It is found that employing $2 \cdot \text{Zn}$ has a direct impact in the catalytic activity. In the case of pinacol the reaction rate was strongly decreased (entry 2) while for $\text{Ph}_2\text{C}(\text{OH})\text{C}(\text{OH})\text{Ph}_2$, it was slightly increased (entry 4). Although the reason for this difference in rate is unclear at this stage, the effect is obviously not only steric in origin.

To evaluate the selectivity of the unencapsulated and encapsulated catalyst, competitive oxidative cleavage experiments were performed in the presence of both substrates. The competitive reaction in the presence of ligand **2** leads to benzophenone and acetone in a ratio of 0.26 (entry 5). The same reaction performed in the presence of capsule $2 \cdot \text{Zn}$ leads to inversion in the selectivity with a product ratio of 3.50 (entry 6). Thus, the preferred product is dependent upon the encapsulation of the catalyst.

- 21 H. Amouri, C. Desmarets and J. Moussa, *Chem. Rev.*, 2012, **112**, 2015–2041.
- 22 D. Fiedler, D. H. Leung, R. G. Bergman and K. N. Raymond, *Acc. Chem. Res.*, 2005, **38**, 349–358.
- 23 T. S. Koblenz, J. Wassenaar and J. N. H. Reek, *Chem. Soc. Rev.*, 2008, **37**, 247–262.
- 24 U. H. Brinker and J.-L. Miesusset, *Molecular Encapsulation: Organic Reactions in Constrained Systems*, John Wiley & Sons, Ltd, Chichester, 2010.
- 25 J. N. H. Reek and S. Pullen, in *Supramolecular Catalysis: New Directions and Developments*, ed. P. W. N. M. van Leeuwen and M. Raynal, Wiley-VCH, Weinheim, Germany, 2002, pp. 255–270.
- 26 L. J. Jongkind, X. Caumes, A. P. T. Hartendorp and J. N. H. Reek, *Acc. Chem. Res.*, 2018, **51**, 2115–2128.
- 27 S. H. A. M. Leenders, R. Gramage-Doria, B. de Bruin and J. N. H. Reek, *Chem. Soc. Rev.*, 2015, **44**, 433–448.
- 28 T. Tateishi, M. Yoshimura, S. Tokuda, F. Matsuda, D. Fujita and S. Furukawa, *Coord. Chem. Rev.*, 2022, **467**, 214612.
- 29 C. T. McTernan, J. A. Davies and J. R. Nitschke, *Chem. Rev.*, 2022, **122**, 10393–10437.
- 30 T. R. Cook and P. J. Stang, *Chem. Rev.*, 2015, **115**, 7001–7045.
- 31 M. M. Conn and J. Rebek, *Chem. Rev.*, 1997, **97**, 1647–1668.
- 32 D. L. Caulder and K. N. Raymond, *Acc. Chem. Res.*, 1999, **32**, 975–982.
- 33 V. F. Slagt, J. N. H. Reek, P. C. J. Kamer and P. W. N. M. van Leeuwen, *Angew. Chem., Int. Ed.*, 2001, **40**, 4271–4274.
- 34 V. Bocokić, A. Kalkan, M. Lutz, A. L. Spek, D. T. Gryko and J. N. Reek, *Nat. Commun.*, 2013, **4**, 2670.
- 35 M. Kuil, T. Soltner, P. W. N. M. van Leeuwen and J. N. H. Reek, *J. Am. Chem. Soc.*, 2006, **128**, 11344–11345.
- 36 V. F. Slagt, P. C. J. Kamer, P. W. N. M. van Leeuwen and J. N. H. Reek, *J. Am. Chem. Soc.*, 2004, **126**, 1526–1536.
- 37 L. J. Jongkind, J. A. A. W. Elemans and J. N. H. Reek, *Angew. Chem., Int. Ed.*, 2019, **58**, 2696–2699.
- 38 I. Jacobs, A. C. T. van Duin, A. W. Kleij, M. Kuil, D. M. Tooke, A. L. Spek and J. N. H. Reek, *Catal. Sci. Technol.*, 2013, **3**, 1955–1963.
- 39 T. Besset, D. W. Norman and J. N. H. Reek, *Adv. Synth. Catal.*, 2013, **355**, 348–352.
- 40 X. Wang, S. S. Nurtila, W. I. Dzik, R. Becker, J. Rodgers and J. N. H. Reek, *Chem.–Eur. J.*, 2017, **23**, 14769–14777.
- 41 L. J. Jongkind and J. N. H. Reek, *Chem.–Asian J.*, 2020, **15**, 867–875.
- 42 A. J. Plajer, A. L. Colebatch, F. J. Rizzuto, P. Proehm, A. D. Bond, R. García-Rodríguez and D. S. Wright, *Angew. Chem., Int. Ed.*, 2018, **57**, 6648–6652.
- 43 Á. García-Romero, A. J. Plajer, L. Álvarez-Miguel, A. D. Bond, D. S. Wright and R. García-Rodríguez, *Chem.–Eur. J.*, 2018, **24**, 17019–17026.
- 44 J. E. Waters, G. Berger, A. J. Peel, R. García-Rodríguez, A. D. Bond and D. S. Wright, *Chem.–Eur. J.*, 2021, **27**, 12036–12040.
- 45 E. S. Yang, A. J. Plajer, Á. García-Romero, A. D. Bond, T. K. Ronson, C. M. Álvarez, R. García-Rodríguez, A. L. Colebatch and D. S. Wright, *Chem.–Eur. J.*, 2019, **25**, 14003–14009.
- 46 Á. García-Romero, J. M. Martín-Álvarez, A. L. Colebatch, A. J. Plajer, D. Miguel, C. M. Álvarez and R. García-Rodríguez, *Dalton Trans.*, 2021, **50**, 13059–13065.
- 47 Á. García-Romero, A. J. Plajer, D. Miguel, D. S. Wright, A. D. Bond, C. M. Álvarez and R. García-Rodríguez, *Inorg. Chem.*, 2020, **59**, 7103–7116.
- 48 Á. García-Romero, J. M. Martín-Álvarez, D. Miguel, D. S. Wright, C. M. Álvarez and R. García-Rodríguez, *Inorg. Chem.*, 2021, **60**, 19206–19218.
- 49 J. M. Lipschultz, G. Li and A. T. Radosevich, *J. Am. Chem. Soc.*, 2021, **143**, 1699–1721.
- 50 B. Cordero, V. Gómez, A. E. Platero-Prats, M. Revés, J. Echeverría, E. Cremades, F. Barragán and S. Alvarez, *Dalton Trans.*, 2008, 2832–2838.
- 51 M. Mantina, A. C. Chamberlin, R. Valero, C. J. Cramer and D. G. Truhlar, *J. Phys. Chem. A*, 2009, **113**, 5806–5812.
- 52 A. Macchioni, G. Ciancaleoni, C. Zuccaccia and D. Zuccaccia, *Chem. Soc. Rev.*, 2008, **37**, 479–489.
- 53 M. Marchini, A. Luisa, G. Bergamini, N. Armaroli, B. Ventura, M. Baroncini, N. Demitri, E. Iengo and P. Ceroni, *Chem.–Eur. J.*, 2021, **27**, 16250–16259.
- 54 V. McKee, O. C. Choon and G. A. Rodley, *Inorg. Chem.*, 1984, **23**, 4242–4248.
- 55 G. Wu, A. Wong and S. Wang, *Can. J. Chem.*, 2003, **81**, 275–283.
- 56 C. H. Devillers, A. K. D. Dimé, H. Cattey and D. Lucas, *C. R. Chim.*, 2013, **16**, 540–549.
- 57 N. Amiri, M. Hajji, T. Roisnel, G. Simonneaux and H. Nasri, *Res. Chem. Intermed.*, 2018, **44**, 5583–5595.
- 58 O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, *J. Appl. Crystallogr.*, 2009, **42**, 339–341.
- 59 H. W. Moon and J. Cornella, *ACS Catal.*, 2022, **12**, 1382–1393.
- 60 M. Magre, J. Kuziola, N. Nöthling and J. Cornella, *Org. Biomol. Chem.*, 2021, **19**, 4922–4929.
- 61 D. H. R. Barton, W. B. Motherwell and A. Stobie, *J. Chem. Soc., Chem. Commun.*, 1981, 1232–1233.
- 62 D. H. R. Barton, J.-P. Finet, W. B. Motherwell and C. Pichon, *Tetrahedron*, 1986, **42**, 5627–5636.
- 63 S. Yasuike, Y. Kishi, S.-I. Kawara and J. Kurita, *Chem. Pharm. Bull.*, 2005, **53**, 425–427.

